As prostate cancer is the second leading cause of death after lung cancer, several diagnostic strategies have been introduced in recent years. Among these prostate-specific antigens, it is widely recognized that this is the simplest and most common clinical endpoint - genetic instability is part of the oncogenic process. Gene mutations involved in DNA repair mechanisms may promote this genetic instability and participate in oncogenesis and metastatic progression. In prostate cancer, abnormalities in DNA repair are primarily due to somatic or constitutional mutations in the BRCA1/2 genes. Treatment options for prostate cancer are currently widely discussed in the media and by urological associations. Focal therapy is expected to have the same oncological efficacy as whole gland therapy with fewer side effects. Accurate diagnosis with multiparametric magnetic resonance imaging (MRI). In this review, we examine the various studies described presently as the molecular targets for personalized prostate cancer therapy.
Fatima, Tizar and Nadia, El Kadmiri
"Personalized Therapy of Prostate Cancer,"
Health Sciences: Vol. 2:
1, Article 1.
Available at: https://doi.org/10.15342/hs.2020.282
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.